{"id":"NCT00596817","sponsor":"H. Lundbeck A/S","briefTitle":"Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes","officialTitle":"A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2009-09","completion":"2009-10","firstPosted":"2008-01-17","resultsPosted":"2014-03-31","lastUpdate":"2014-03-31"},"enrollment":639,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Vortioxetine (Lu AA21004)","otherNames":["Brintellix"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine: 5 or 10 mg","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.","primaryOutcome":{"measure":"Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator","timeFrame":"Within first 24 weeks of the double-blind period","effectByArm":[{"arm":"Placebo","deltaMin":26,"sd":null},{"arm":"Vortioxetine: 5 or 10 mg","deltaMin":13.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0035"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22495621","31818787","27780334"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":639},"commonTop":["Nausea","Headache","Nasopharyngitis","Accidental overdose","Dizziness"]}}